NCT06558188View on ClinicalTrials.gov

Combined Anabolic Therapy

PHASE4RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 3, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

July 1, 2027

Conditions
Osteoporosis, PostmenopausalOsteoporosis
Interventions
DRUG

Romosozumab

romosozumab 210 milligrams monthly

DRUG

Teriparatide

teriparatide 20 micrograms daily

Trial Locations (1)

02114

RECRUITING

Massachusetts General Hospital, Boston

All Listed Sponsors
collaborator

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

lead

Massachusetts General Hospital

OTHER